Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994, 46:157-203.
Bard J.A., Zgombick J., Adham N., Vaysse P., Branchek T.A., Weinshank R.L. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem 1993, 268:23422-23426.
Martin-Cora F.J., Pazos A. Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br J Pharmacol 2004, 141:92-104.
Hedlund P.B. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology 2009, 206:345-354.
Hedlund P.B., Sutcliffe J.G. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 2004, 25:481-486.
Mnie-Filali O., Lambas-Senas L., Scarna H., Haddjeri N. Therapeutic potential of 5-HT7 receptors in mood disorders. Curr Drug Targets 2009, 10:1109-1117.
Mnie-Filali O., Lambas-Senas L., Zimmer L., Haddjeri N. 5-HT7 receptor antagonists as a new class of antidepressants. Drug News Perspect 2007, 20:613-618.
Lancelot S., Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 2010, 31:411-417.
Lee C.M., Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006, 27:310-316.
Leopoldo M., Berardi F., Colabufo N.A., Contino M., Lacivita E., Niso M., et al. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J Med Chem 2004, 47:6616-6624.
Pittala V., Salerno L., Modica M., Siracusa M.A., Romeo G. 5-HT7 receptor ligands: recent developments and potential therapeutic applications. Mini-Rev Med Chem 2007, 7:945-960.
Thomas D.R., Atkinson P.J., Hastie P.G., Roberts J.C., Middlemiss D.N., Price G.W. [3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues. Neuropharmacology 2002, 42:74-81.
Varnas K., Thomas D.R., Tupala E., Tiihonen J., Hall H. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H]SB-269970. Neurosci Lett 2004, 367:313-316.
Andries J., Lemoine L., Le Bars D., Zimmer L., Billard T. Synthesis and biological evaluation of potential 5-HT7 receptor PET radiotracers. Eur J Med Chem 2011, 46:3455-3461.
Bojarski A.J. Pharmacophore models for metabotropic 5-HT receptor ligands. Curr Top Med Chem 2006, 6:2005-2026.
Lovell P.J., Bromidge S.M., Dabbs S., Duckworth D.M., Forbes I.T., Jennings A.J., et al. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). J Med Chem 2000, 43:342-345.
Lemoine L., Andries J., Le Bars D., Billard T., Zimmer L. Comparison of 4 Radiolabeled Antagonists for Serotonin 5-HT7 Receptor Neuroimaging: Toward the First PET Radiotracer. J Nucl Med 2011, 52:1811-1818.
Poon C.Y., Chiu P. A synthesis of the tetracyclic carboskeleton of isaindigotidione. Tetrahedron Lett 2004, 45:2985-2988.
Lemaire C., Plenevaux A., Aerts J., Del Fiore G., Brihaye C., Le Bars D., et al. Solid phase extraction-an alternative to the use of rotary evaporators for solvent removal in the rapid formulation of PET radiopharmaceuticals. J Labelled Comp Radiopharm 1999, 42:63-75.
ACD/Labs.
Calculator Plugins were used for structure property prediction and calculation, Marvin 5.11.5, 2013, ChemAxon. http://www.chemaxon.com.
Crich D., Crich D., Mo X.-S. One Pot Selective 5'-Oxidation/Olefination of 2'-Deoxynucleosides. Synlett 1999, 1999:67-68.
Zoute L., Kociok-Köhn G., Frost C.G. Rhodium-Catalyzed 1,4-Additions to Enantiopure Acceptors: Asymmetric Synthesis of Functionalized Pyrrolizidinones. Org Lett 2009, 11:2491-2494.
Liu J.C., Yang Y.S., Ji R.Y. A Practical and Efficient Preparation of (S)-2-Benzylsuccinic Acid: A Key Acid Synthon of KAD-1229. Synth Commun 2004, 34:2633-2640.
Le Bars D. Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomography. J Fluorine Chem 2006, 127:1488-1493.
Le Bars D., Lemaire C., Ginovart N., Plenevaux A., Aerts J., Brihaye C., et al. High-Yield Radiosynthesis and Preliminary In Vivo Evaluation of p-[18F]MPPF, a Fluoro Analog of WAY-100635. Nucl Med Biol 1998, 25:343-350.
Badarau E., Suzenet F., Bojarski A.J., Fînaru A.L., Guillaumet G. Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: Synthesis and biological evaluation. Bioorg Med Chem Lett 2009, 19:1600-1603.
Volk B., Barkóczy J., Hegedus E., Udvari S., Gacsályi I., Mezei T., et al. (Phenylpiperazinyl-butyl)oxindoles as Selective 5-HT7 Receptor Antagonists. J Med Chem 2008, 51:2522-2532.
Clark D.E. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003, 8:927-933.
Kelder J., Grootenhuis P.D.J., Bayada D.M., Delbressine L.P.C., Ploemen J.-P. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs. Pharm Res 1999, 16:1514-1519.
Norinder U., Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev 2002, 54:291-313.
Lacan G., Plenevaux A., Rubins D.J., Way B.M., Defraiteur C., Lemaire C., et al. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging 2008, 35:2256-2266.
Elsinga P.H., Hendrikse N.H., Bart J., Vaalburg W., van Waarde A. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004, 10:1493-1503.
